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Abstract
Background: Intravenous immunoglobulin (IVIG) proved to be an efficient anti-inflammatory treatment for a
growing number of neuroinflammatory diseases and protects against the development of experimental
autoimmune encephalomyelitis (EAE), a widely used animal model for multiple sclerosis (MS).
Methods: The clinical efficacy of IVIG and IVIG-derived F(ab’)2 fragments, generated using the streptococcal cysteine
proteinase Ide-S, was evaluated in EAE induced by active immunization and by adoptive transfer of myelin-specific
T cells. Frequency, phenotype, and functional characteristics of T cell subsets and myeloid cells were determined by
flow cytometry. Antibody binding to microbial antigen and cytokine production by innate immune cells was
assessed by ELISA.
Results: We report that the protective effect of IVIG is lost in the adoptive transfer model of EAE and requires
prophylactic administration during disease induction. IVIG-derived Fc fragments are not required for protection against
EAE, since administration of F(ab’)2 fragments fully recapitulated the clinical efficacy of IVIG. F(ab’)2-treated mice showed
a substantial decrease in splenic effector T cell expansion and cytokine production (GM-CSF, IFN-γ, IL-17A) 9 days after
immunization. Inhibition of effector T cell responses was not associated with an increase in total numbers of Tregs but
with decreased activation of innate myeloid cells such as neutrophils, monocytes, and dendritic cells. Therapeutically
effective IVIG-derived F(ab’)2 fragments inhibited adjuvant-induced innate immune cell activation as determined by IL-
12/23 p40 production and recognized mycobacterial antigens contained in Freund’s complete adjuvant which is
required for induction of active EAE.
Conclusions: Our data indicate that F(ab’)2-mediated neutralization of adjuvant contributes to the therapeutic efficacy
of anti-inflammatory IgG. These findings might partly explain the discrepancy of IVIG efficacy in EAE and MS.
Keywords: Intravenous immunoglobulin, Experimental autoimmune encephalomyelitis, Multiple sclerosis, T cell,
Dendritic cell, Innate immunity, Adjuvant, Mycobacteria
Background
High-dose therapy with intravenous immunoglobulin
(IVIG), obtained from the plasma of several thousand indi-
viduals, is an efficient anti-inflammatory and immunomod-
ulatory treatment for a growing number of autoimmune
neuroinflammatory diseases. Based on randomized con-
trolled clinical trials (RCT), FDA-approved indications in-
clude chronic inflammatory demyelinating polyneuropathy
and multifocal motor neuropathy [1]. IVIG is also effective
in some patients with worsening myasthenia gravis and is
beneficial as a second-line therapy for dermatomyositis and
stiff-person syndrome [1]. IVIG therapy was shown to sup-
press clinical disease development in experimental auto-
immune encephalomyelitis (EAE) [2–8], an animal model
for multiple sclerosis (MS). However, subsequent RCTs
demonstrated that IVIG therapy has no beneficial effects
in reducing relapse rates and clinical disease progression
in patients with relapsing-remitting and secondary-
progressive multiple sclerosis (MS) [9–12], which led to* Correspondence: jan.luenemann@uzh.ch1Institute of Experimental Immunology, Laboratory of Neuroinflammation,
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the conclusion that IVIG is ineffective and not recom-
mended for patients with MS [1, 13, 14].
IVIG preparations contain antibodies directed against
a broad range of pathogens, as well as numerous foreign
and self antigens. IgG molecules consist of two func-
tional domains, the antigen-binding fragment F(ab’)2,
which determines the specificity of the antibody mol-
ecule, and the constant, or fragment crystallizable (Fc)
region, which is critical for the initiation of effector re-
sponses such as activation of the complement pathway
or crosslinking of Fc-receptors on innate immune ef-
fector cells. In autoantibody-mediated animal models of
autoimmune diseases such as idiopathic thrombocytope-
nic purpura (ITP), rheumatoid arthritis, and nephrotoxic
nephritis, the IgG Fc domain appears to be essential in
mediating the protective effects of IVIG [15–19]. The
clinical efficacy of IVIG in EAE, a T cell-driven auto-
immune disease model, has been attributed to IVIG-
induced inhibition of effector T cells and reciprocal ex-
pansion of CD4+FoxP3+ regulatory T cells (Tregs), but
divergent results were obtained on whether the protect-
ive effects of IVIG in EAE are Fc-dependent [4, 7, 8].
Here, we show that the protective effect of IVIG is
dose-dependent, requires prophylactic administration
during priming, and is lost upon adoptive transfer of
encephalitogenic T cells to induce EAE. IVIG-derived
F(ab’)2 fragments inhibit immunostimulatory adjuvant
activity necessary for disease induction and are suffi-
cient to mediate protection from EAE development.
Methods
Purification of Ide-S
The protein sequence of Ide-S (NCBI reference se-
quence: NP_269065.1; AA28-339) was reverse translated
into an E. coli codon-optimized DNA sequence using
CLC Main Workbench (Qiagen). The resultant sequence
was synthesized by GeneArtTM gene synthesis (Thermo
Fischer Scientific) and subcloned in a modified pET28a
(GE Healthcare) vector containing an N-terminal deka-
HIS tag. MC1060/pWTZ594 E. coli was used for cloning
and plasmid amplification. The final plasmid was trans-
ferred into BL21 E. coli (NEB). For protein expression,
bacteria were grown to an OD600 nm of 0.3–0.4 and ex-
pression was induced by addition of 0.1 mM IPTG
(AppliChem) for 3 h at 37 °C. The bacteria pellet was
suspended in PBS containing 20 μg/ml DNAse (Sigma)
and 1.6 mM PMSF. Bacteria were lysed by sonication
and Ide-S was purified by immobilized metal ion affinity
chromatography (HisTrap HP columns, GE Healthcare)
using Äkta prime plus (GE Healthcare). Successful puri-
fication was monitored by SDS-PAGE and Coomassie®
Brilliant Blue R250 staining. Finally, the protein was di-
alyzed to PBS, sterile filtered through a 0.2 μM filter,
supplemented with 20 % glycerol and adjusted to a
concentration of 1 mg/ml before snap-freezing in li-
quid nitrogen and storage at −80 °C until further use.
Generation of F(ab’)2 fragments from IVIG
The streptococcal cysteine proteinase Ide-S was used to
generate F(ab’)2 fragments from IVIG [20]. Privigen
(CSL Behring) was used as IVIG preparation throughout
the study. Two milligrams of Ide-S were incubated with
3 ml (300 mg) IVIG at room temperature (RT) for at
least 8 h (or overnight). F(ab’)2 was separated from
uncut IgG and Fc using a HiLoad 26/60 Superdex 75
prep grade column (GE Healthcare) and Äkta Purifier
(GE Healthcare) using PBS as running buffer. The
F(ab’)2 containing fraction was concentrated by ammo-
nium sulfate precipitation by adding twice the volume of
saturated ammonium sulfate solution and incubation for
1 h at RT. After centrifugation for 30 min at 3000×g, the
supernatant was discarded and the precipitate suspended
in PBS and extensively dialyzed to PBS. To remove
remaining full-length IgG, a protein A sepharose (GE
Healthcare) column was self-packed by filling 2 ml protein
A sepharose slurry in a Supelco polypropylene SPE tube
containing PE frits with 20 μM porosity (Sigma-Aldrich)
and F(ab’)2 was applied by gravity flow. The column flow-
through, containing the F(ab’)2, was concentrated using
Amicon Ultra 15-ml centrifugal filters (Merck Millipore)
with a molecular weight cutoff of 10 kDa according to the
manufacturer’s instructions until a final concentration of
35 to 45 mg/ml was obtained. Successful purification of
F(ab’)2 was confirmed by SDS-PAGE and Coomassie® Bril-
liant Blue R250 staining. Finally, the solution was sterile-
filtered through a 0.2-μM filter and stored at 4 °C until
further use.
Mice
C57Bl/6 wt mice (B6) were purchased from Janvier.
C57Bl/6 TCRMOG transgenic mice (2D2) mice were kindly
provided by Vijay K. Kuchroo (Harvard Institutes of
Medicine) [21]. 2D2 mice were genotyped as previously
described [21]. All mice were bred and housed in the
animal facility of the University of Zürich in individually
ventilated cages under specific pathogen free conditions
according to Swiss animal laws. All animal protocols were
approved by the cantonal veterinary office of Zürich,
Switzerland (license numbers 862012 and 702015).
Induction and assessment of active EAE
EAE was induced in B6 mice as previously described
[22, 23] with minor adaptations. In brief, MOG35–55 pep-
tide (MEVGWYRSPFSRVVHLYRNGK; GenScript) was
dissolved in PBS to obtain a final concentration of 1 mg/
ml. On the day of immunization, 100 μl peptide solution
was emulsified in 100 μl complete Freund’s adjuvant (CFA;
Difco Laboratories) supplemented with 3.3 mg/ml dried,
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inactivated Mycobacterium tuberculosis (M. Tuberculosis
Des. H37 Ra, Difco Laboratories, Detroit, USA) by vigor-
ously mixing the solution for 15 min via transfer in between
two syringes connected to each other by a Luer-Lock con-
nector. Six- to eight-week-old female B6 mice or TCRMOG
transgenic mice were used for immunization. Mice were
anesthetized by isoflurane inhalation and immunized by s.c.
injection of 100-μl emulsion on both sides of the lateral ab-
domen using a 24 G × 1” needle. In addition, mice received
200 ng pertussis toxin (pertussis toxin in Glycerol, List Bio-
logical Laboratories) i.p. on the day of immunization and
2 days thereafter. Animal weight and general health and
disease progression were monitored daily. The following
scoring system was applied: 0—no detectable signs of EAE;
0.5—distal limp tail paralysis; 1.0—complete limp tail par-
alysis; 1.5—limp tail paralysis and hindlimb weakness;
2.0—unilateral partial hindlimb paralysis; 2.5—bilateral par-
tial hindlimb paralysis; 3.0—complete bilateral hindlimb
paralysis; 3.5—complete bilateral hindlimb paralysis and
partial forelimb paralysis; 4.0—moribund; 5.0—dead. Mice
were euthanized by CO2 inhalation if a disease score of 3
was maintained for more than 7 days, a disease score of 3.5
was maintained for more than 3 days, or a disease score of
4 was reached.
Induction and assessment of adoptive transfer EAE
Adoptive transfer EAE was induced as previously described
[24, 25]. Donor mice (2D2) were immunized with MOG35–
55 peptide emulsified in CFA as described above. On day 7
post immunization, leukocytes from the spleen and drain-
ing lymph nodes were purified (see below). Cells were re-
stimulated in vitro by cultivation for 2 days at a density
of 1 × 107 cells/ml at standard cell culture conditions
(SCCC; 37 °C and 5 % CO2 in a humidified incubator)
in 12-cm cell culture dishes (Greiner) in RPMI 1640
medium (Life Technologies; 10 ml per dish) supple-
mented with 50 U/ml penicillin/streptomycin (P/S) and
10 % fetal calf serum (FCS) (referred to as R10
medium), 10 ng/ml recombinant IL-23 (eBioscience),
and 20 μg/ml MOG35–55 peptide. Recipient mice were
sublethally irradiated with 550 rad 1 day before i.p. in-
jection of 1 × 107 restimulated cells. Disease progression
was monitored as described above.
Leukocyte isolation from spleen and lymph nodes
Mice were euthanized by CO2 inhalation. Spleen and in-
guinal lymph nodes were removed and mechanically dis-
rupted using scissors. Disrupted tissues were incubated
at 37 °C in 3 ml PBS containing 0.4 mg/ml Collagenase
D (Roche) and 0.1 mg/ml DNA se (Sigma) for 30 min.
The reaction was stopped by adding EDTA to a final
concentration of 10 mM. Thereafter, a syringe plunger
was used to further disrupt the tissue by filtering
through a 70-μm mesh. Cells were washed once with
PBS. Red blood cells (RBC) were lysed using RBC lysis
buffer (Biolegend) according to the manufacturer’s
instructions. CASY® counter (Innovatis) was used to de-
termine cell numbers.
Flow cytometry analysis of murine splenocytes
For the analysis of cell surface antigens, 2 × 107 cells
were suspended in 50 μl PBS supplemented with fluoro-
chrome coupled monoclonal antibodies. After incuba-
tion on ice for 30 min, cells were washed twice with
200 μl PBS. For intracellular cytokine staining, 2 × 107
cells were incubated per well of a 96-well V bottom plate
in 100 μl R10 supplemented with 50 ng/ml PMA
(Sigma), 500 ng/ml Ionomycin (Sigma), and 10 μg/ml
Brefeldin A (Sigma) for 4 h at SCCC. For intracellular
detection of cytokines and transcription factors, FoxP3
transcription factor staining buffer set (eBioscience) was
used according to the manufacturer’s instructions. All
samples were acquired using LSR Fortessa (BD). Fluoro-
chrome labeled antibodies were purchased from Biolegend
(anti-CD8α-FITC or anti-CD8α-BV785 (clone 53-6.7),
anti-CD11b-APC-Cy7 (clone M1/70), anti-CD11c-PE-
Cy7 (clone N418), anti-CD25-BV605 (clone PC61),
anti-CD44-Pacific Blue (clone IM7), anti-CD80-PE
(clone 16-10A1), anti-IL-17A-PE-Cy7 (clone TC11-
18H10), anti-IFN-γ-FITC (clone XMG1.2), anti-Ly6C-
PerCP -Cy5.5 (clone HK1.4), anti-Ly6G-APC (clone
1A8), and anti-MHC-II-Pacific Blue (I-A/I-E, clone
M5/114.15.2)), eBioscience (anti-CD19-Alexa-Fluor700
(clone eBio1D3 (1D3), anti-FoxP3-PerCP-Cy5.5 (clone
FJK-16s), and anti-GM-CSF-PE (clone MP1-22E9)),
and BD Pharmingen (anti-CD4-APC (clone RM4-5)
and anti-CD62L-PE-CF594 (clone MEL-14)). Fixable
L/D staining kits (aqua/amcyan and near-IR) were
purchased from Invitrogen.
Analysis of neutrophil cell death
Mouse bone marrow-derived neutrophils were isolated
from B6 mice as previously described [26]. Cell death
was assessed using annexin V/propidium-iodide (PI) and
DNA fragmentation assays by flow cytometry (FACS-
Verse; Becton Dickinson Biosciences), as previously de-
scribed [27, 28]. PI was purchased from Sigma-Aldrich
(Buchs, Switzerland). Recombinant hexahistidine-tagged
GFP-annexin V, Fas-Ligand (Fas-L) and Fas-L cross-linker
were kind gifts from Prof. T. Kaufmann, Institute of
Pharmacology, University of Bern, Bern, Switzerland.
In vitro stimulation of splenocytes with M. tuberculosis
Mouse splenocytes were isolated as described above. 5 ×
105 splenocytes were plated in 96-well U-bottom plates
(Greiner) in R10 medium and incubated in the presence
or absence of F(ab’)2 fragments with 0.001, 0.01, and
0.1 μg/ml dried, inactivated M. tuberculosis (Des. H37
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Ra, Difco Laboratories) suspended in R10 medium for
12 h under SCCC.
IL-12/23 p40 ELISA
IL-12/23 p40 was detected in culture supernatants by
ELISA using the monoclonal antibodies C15.6 and C17.8
according to the manufacturer’s recommendations
(Mouse IL-12/23 (p40) ELISA; Mabtech).
M. tuberculosis binding ELISA
Dried, inactivated M. tuberculosis (Des. H37 Ra, Difco La-
boratories, Detroit, USA) was suspended and diluted to a
final concentration of 50 mg/ml in 50 mM carbonate buf-
fer (pH 9.6). Per well, 50 μl diluted M. tuberculosis were
coated overnight at 4 °C to flat-bottom 96-well plates
(MaxiSorp®, Nunc). After washing extensively with PBS
containing 0.1 % Tween20 (wash buffer), wells were
blocked with PBS containing 1 % bovine serum albumin
and 0.05 % Tween20 (blocking buffer) for 2 h at RT.
Thereafter, all liquid was removed, and IVIG, F(ab’)2, or
Rituximab (Mabtera, Roche) were diluted to 1, 0.1, 0.01,
and 0.001 μg/ml with blocking buffer and added to the
wells. After incubation for 1 h at RT, plates were
washed with wash buffer and incubated for 1 h with bi-
otinylated mouse-anti-human IgG (BD, clone G18-145)
diluted in blocking buffer to a final concentration of
0.5 μg/ml. Wells were washed again and incubated with
horseradish peroxidase (HRP) coupled streptavidin
(Mabtech). 1-StepTM Ultra TMB-ELISA Substrate So-
lution (ThermoFischer Scientific) was used to detect
HRP activity. The reaction was stopped by addition of
2 M NaCl, and colorimetric signals were evaluated by
measuring the optical density at 450 nm.
Statistics
Statistics were performed using GraphPad Prism 5
(GraphPad Software Inc.). p values below 0.05 were con-
sidered significant.
Results
Clinical efficacy of IVIG in EAE requires high-dose treat-
ment and active immunization
We first evaluated the IVIG dose required for its pro-
tective effect. IVIG was given daily starting 1 day before
EAE immunization. High-dose IVIG (1 g/kg) completely
protected animals from disease development whereas
0.1 g/kg only led to partial protection (Fig. 1a). Continu-
ous administration of IVIG prevented EAE development,
termination of treatment at day 6 led to a delayed dis-
ease onset and reduced severity and treatment from day
7 on exacerbated EAE symptoms (Fig. 1b) indicating
that IVIG is required at high dose and continuously for
its protective effect and active during T cell priming in
response to active vaccination. In order to investigate
the therapeutic potential of IVIG independent of adju-
vant administration and T cell priming, we next deter-
mined its clinical efficacy in the adoptive transfer model
of EAE, in which disease is induced by peripheral intro-
duction of pre-activated myelin-specific effector T cells.
Spleen and lymph node (LN)-derived leukocytes from
MOG35–55 peptide immunized mice carrying the trans-
genic 2D2 T cell receptor recognizing MOG35–55 peptide
[21] were restimulated in vitro with IL-23 and MOG35–
55 peptide and adoptively transferred into naïve mice.
High-dose IVIG treatment (1 g/kg) in recipient mice
was started 1 day before transfer and continued through-
out the experiment. In contrast to its therapeutic efficacy
in active EAE, IVIG treatment was ineffective in protect-
ing recipient mice from disease development following
adoptive transfer of myelin-specific T cells (Fig. 1c).
These data show that IVIG protects from EAE develop-
ment if administered during disease induction following
active immunization but does not significantly inhibit
the encephalitogenic potential of primed effector T cells.
Fc fragments are not required for the protective effect of
IVIG in EAE
To determine whether the protective effect of IVIG in
EAE requires the presence of Fc fragments as reported
for several antibody-mediated autoimmune disease
models [15–19], the Fc portion of IVIG-derived IgG was
removed by cleavage with Ide-S [20] and F(ab’)2 was
purified. Successful purification was confirmed by SDS-
PAGE and Coomassie® Brilliant Blue staining (Fig. 2a).
EAE-immunized mice were treated with equimolar
amounts of IVIG, F(ab’)2, or buffer starting 1 day before
immunization. F(ab’)2 fragments completely recapitu-
lated the protective effect of IVIG for both disease sever-
ity (Fig. 2b) and incidence (Fig. 2c) indicating that Fc
fragments are not required for the protective effect of
IVIG during EAE development.
IVIG-derived F(ab’)2 fragments inhibit expansion and
cytokine production of activated effector T cells
In order to determine T cell regulatory mechanisms re-
sponsible for the protective effect of IVIG during disease
induction, we analyzed frequencies, absolute numbers,
and cytokine production of CD44−CD62L+FoxP3− naïve,
FoxP3+ regulatory, and CD44+FoxP3−-activated effector
CD4+ T cells in F(ab’)2-treated and non-treated mice
9 days after immunization. F(ab’)2 treatment was initi-
ated 1 day prior to immunization and maintained until
day 9. As reported previously [4], F(ab’)2 treatment was
associated with increased frequencies of splenic Tregs
(Fig. 3a). In absolute numbers, however, F(ab’)2 did not
expand Tregs but decreased the numbers of activated
CD4+ T cells (Fig. 3b). Furthermore, F(ab’)2-treated mice
showed substantially reduced frequencies and absolute
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numbers of CD4+ T cells producing INF-γ, GM-CSF, or
IL-17A (Fig. 3c, d). These data indicate that the protective
effect of IVIG-derived F(ab’)2 fragments is associated with
a marked reduction in activated effector T cells producing
cytokines crucial for the development of EAE [25, 29].
Reduced phenotypic innate immune cell activation upon
F(ab’)2 treatment in vivo
Induction of active EAE following immunization requires
administration of adjuvant such as complete Freund’s ad-
juvant (CFA)-contained inactivated mycobacteria, e.g., M.
tuberculosis, leading to innate immune cell activation and
effector T cell expansion [30–32]. To evaluate whether
IVIG-derived F(ab’)2 fragments inhibit innate immune cell
activation in response to immunization, we analyzed fre-
quencies of leukocyte subsets (Ly6G+CD11cint neutro-
phils, Ly6ChighCD11b+ monocytes and CD11chighMHC
class II+ CD8− or CD8+ DCs) and profiled their expression
of cell surface markers associated with activation and anti-
gen presentation (MHC class II, CD80). F(ab’)2 treatment
affected the composition of innate leukocytes leading to
reduced numbers of neutrophils and increased numbers
of monocytes 9 days after immunization (Fig. 4a). In all of
the innate immune cell subsets analyzed, F(ab’)2 treatment
led to a marked reduction of MHC class II and CD80
expression (Fig. 4b), indicating that the protective effect of
IVIG-derived F(ab’)2 fragments is associated with both
reduced innate immune activation and limited expansion
of effector T cells.
F(ab’)2 treatment does not induce apoptosis in murine
neutrophils
Neutrophils have been shown to play an important role
during EAE disease initiation as they can amplify auto-
immune CNS infiltrates by maturing local antigen-
presenting cells and neutrophil depletion ameliorates EAE
Fig. 1 Efficacy of IVIG in active vs. adoptive transfer EAE. B6 mice were immunized with MOG35–55 peptide emulsified in CFA and treated i.p. with
IVIG or PBS starting 1 day before immunization and every day thereafter (or as indicated). Titration (a) and timing (b) of IVIG treatment. Means
and SEM are shown. n = 4 animals per group. c EAE was induced by adoptive transfer of in vitro restimulated leukocytes derived from MOG35–55
and CFA immunized 2D2 mice. Mice received daily i.p. injections of IVIG or buffer starting 1 day before immunization. Means and SEM are shown.
n = 10 animals per group
Fig. 2 Fc is not required for the protective effect of IVIG. a Coomassie® Brilliant Blue stained non-reducing (left) or reducing (right) SDS-PAGE showing IVIG
and purified F(ab’)2. B6 mice were immunized with MOG35–55 peptide emulsified in CFA and injected i.p. with IVIG, F(ab’)2, or buffer starting 1 day before
immunization. Disease severity (b) and incidence (c) are shown. n= 12 animals per group. Individual curves in (b) were compared to buffer treated animals
using two-way ANOVA and Bonferroni posttest. ***p≤ 0.001
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development [33]. IVIG was shown to contain Fas and
Siglec-9 specific antibodies, which can induce apoptosis in
human neutrophils [28, 34, 35]. In murine neutrophils,
IVIG (supplied by the Japan Blood Products Organization,
Osaka, Japan; 0.3 and 1 g/kg, administered intraperitone-
ally) was reported to limit inhibition of neutrophil apoptosis
induced by lipopolysaccharide (LPS) stimulation, potentially
by blocking LPS-mediated effects, although no direct pro-
apoptotic activity of IVIG could be demonstrated [36]. We
therefore examined whether F(ab’)2 fragments induce apop-
totic cell death in murine neutrophils as a potential mech-
anism contributing to the protective effect of IVIG during
EAE development. Apoptotic cell death was determined by
annexin V, PI staining, and DNA fragmentation in ex vivo
cultured neutrophils in the presence of 13.3 mg/ml F(ab’)2,
a concentration which has been reported to readily induce
apoptosis of human neutrophils [28] and crosslinked Fas-L
as positive control (Fig. 5). Murine neutrophils were resist-
ant to apoptotic cell death induced by human F(ab’)2 frag-
ments arguing against F(ab’)2-mediated cytotoxicity of
neutrophils as a potential mechanism of IVIG efficacy in
EAE.
IVIG-derived F(ab’)2 fragments recognize mycobacterial
antigens in CFA and inhibit mycobacterial-induced IL-12/
23 p40 production
Decreased innate immune cell activation in response to
CFA/MOG35–55 peptide-immunization during F(ab’)2
treatment suggests that IVIG might contain antibodies
specific for mycobacterial antigens which could reduce
the immunostimulatory potential of CFA and, thus, impair
the immunogenicity of EAE immunization. Indeed,
Fig. 3 IVIG-derived F(ab’)2 fragments inhibit effector T cell differentiation and cytokine production. B6 mice were either left untreated (naïve) or
immunized with MOG35–55 peptide emulsified in CFA and injected i.p. with F(ab’)2 (0.33 g/kg) or buffer starting 1 day before immunization and
every day thereafter. Analysis of splenic CD4+ T cells 9 days after immunization is shown. Percentage (a) and absolute numbers (b) of the
indicated CD4+ T cell subsets. Frequency (c) and absolute numbers (d) of CD4+ T cells producing IFN-γ, GM-CSF, or IL-17A following restimulation
with PMA/ionomycin. Statistics were performed by Mann Whitney test. *p≤ 0.05, **p≤ 0.01, ***p ≤ 0.001
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bacterial antigens are recognized by IVIG [37, 38], and
IVIG was reported to be therapeutically active in M. tu-
berculosis infection in mice [39]. To determine whether
IVIG-derived F(ab’)2 fragments bind to CFA-contained
mycobacterial antigens, the mycobacterial fraction of CFA
was coated to ELISA plates and incubated with IVIG,
IVIG-derived F(ab’)2, and a control monoclonal antibody
(Rituximab). Both IVIG and IVIG-derived F(ab’)2 frag-
ments readily bound mycobacterial antigens (Fig. 6a). We
next determined whether IVIG-derived F(ab’)2 treatment
would inhibit the immunostimulatory efficacy of the
mycobacterial fraction of CFA to elicit IL-12/23 p40 pro-
duction, a cytokine crucial for EAE development [31, 40].
Challenge of murine splenocytes with dried, inactivated
M. tuberculosis led to a dose-dependent increase in IL-12/
23 p40 secretion, which was inhibited in the presence of
IVIG-derived F(ab’)2 fragments (Fig. 6b). These data indi-
cate that IVIG contains CFA-binding antibodies and in-
hibits the immunostimulatory activity of CFA-containing
mycobacterial antigens required for induction of active
EAE.
Discussion
We demonstrate that high-dose IVIG treatment protects
from EAE development if administered during disease
induction. These findings are in line with a previous study
demonstrating that IVIG is only effective in EAE if admin-
istered prophylactically but does not attenuate the disease
course or the degree of CNS inflammation if administered
after onset of symptoms [41]. In the aforementioned
study, brain and cervical spinal cord inflammation
tended to be higher in mice that received IVIG at
day 8–9, i.e., after onset of clinical symptoms. In our
hands, IVIG treatment of actively induced EAE exac-
erbated disease if administered continuously after day
7. Myelin-specific IgG does not induce but exacer-
bates EAE if administered into already diseased mice
[42] indicating that pathogenic antibodies can acceler-
ate but not induce EAE development. The observed
exacerbation of EAE pathology following IVIG admin-
istration after day 7 suggests that IVIG indeed
contains IgG species that could promote disease de-
velopment such as antibodies targeting myelin struc-
tures or neutralizing anti-inflammatory mediators
[43–45], but the exact mechanisms responsible for
this finding remain to be identified.
Although IVIG was reported to enter the CNS and is
localized to inflammatory lesions during EAE [6], we
show that its therapeutic efficacy is lost in the adoptive
transfer EAE model indicating that IVIG interferes with
Fig. 4 F(ab’)2 treatment impairs innate immune cell activation. B6 mice were either left untreated (naïve) or immunized with MOG35–55 peptide
emulsified in CFA and injected i.p. with F(ab’)2 (0.33 g/kg) or buffer starting 1 day before immunization and every day thereafter. Analysis of splenic
neutrophils, monocytes, and dendritic cell subsets 9 days after immunization is shown. Frequencies (a) and absolute numbers (b) of the indicated
leukocyte subset and cell surface expression levels of MHC class II (c) and CD80 (d). MFI median fluorescence intensity. Statistics were performed by
Mann Whitney test. *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001
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early stages of disease development but does not inhibit
already primed and pre-activated encephalitogenic T
cells or inflammatory lesion formation within the CNS.
Here, Privigen (CSL Behring) was used throughout the
study. Different IVIG preparations are frequently treated
as interchangeable products clinically, but differences in
product preparations exist that may impact tolerability
and activity in selected applications [46]. Further studies
are required to determine whether our findings are ap-
plicable to other IVIG preparations as well. Our study,
however, extends the findings by Achiron and colleagues
who reported that IVIG treatment with Gamimune N
(Bayer), while therapeutically beneficial in EAE induced
with guinea pig myelin basic protein in complete
Fig. 5 IVIG-derived F(ab’)2 fragments do not induce cell death of murine neutrophils. Flow cytometric analysis of cell death by annexin V-FITC/PI
staining (a) or DNA fragmentation (b) of cells cultured in presence of 13.3 mg/ml F(ab’)2 or 110 ng/ml crosslinked Fas-L (positive control). Results
of 15-hour cultures are shown. Data are representative of three independent experiments. Quantitative analysis is indicated as the percentage
representative of each quadrant (a) or of gated subdiploid DNA (b)
Fig. 6 IVIG-derived F(ab’)2 fragments bind to CFA-contained mycobacterial antigens and inhibit Mycobacteria-induced IL-12/23 p40 production in vitro.
a Binding of IVIG, IVIG-derived F(ab’)2, or Rituximab to Mycobacteria-coated ELISA plates. b Murine splenocytes were incubated overnight with myco-
bacteria in the presence or absence of F(ab’)2. IL-12/23 p40 secretion into culture supernatants was measured by ELISA. IL-12/23 p40 production in the
presence of 0.1 μg/ml mycobacteria in the absence of F(ab’)2 was set to 100 %, and relative IL-12/23 p40 production was calculated for each
experiment. Mean + SEM of three independent experiments is shown. Statistics were performed by paired T test. *p≤ 0.05
Quast et al. Journal of Neuroinflammation  (2016) 13:42 Page 8 of 11
Freund’s adjuvant, had no effect in relation to onset,
duration, and severity in the adoptive transfer EAE
model in Lewis rats [47].
IVIG preparations were shown to suppress the prolif-
eration of human myelin- and tetanus toxoid-specific T
cells (Octagam, Octapharma and Venimmun, Sanofi-
Aventis) [48], to induce apoptosis in human leukemic
cells of lymphocyte and monocyte lineage (Gammagard,
Baxalta, and Sandoglobulin, CSL Behring) [49] and to
confer anergy to T cells specific for myelin basic protein
(Sandoglobulin, CSL Behring) [50]. The lack of efficacy
in preventing EAE development in mice following adop-
tive transfer of myelin-specific T cells argues against a
function of IVIG in inhibiting the viability or expansion
of pathogenic effector T cells in vivo. Moreover, it does
not support a major role for IVIG in promoting oligo-
dendrocyte apoptosis during EAE as discussed by
Weishaupt and colleagues (Venimmun, Sanofi-Aventis
and Sandoglobulin, CSL Behring) [51] nor in promoting
myelin repair as suggested by Humle Jorgensen et al. [5]
since oligodendrocyte injury and demyelination contrib-
ute to the development of both active and adoptive
transfer EAE. This being said, our data do not exclude
the possibility that other IVIG preparations than the
ones tested in our study (Privigen) and by Achiron et al.
[47] (Gamimune N) might be effective in limiting adop-
tive transfer EAE development.
The anti-inflammatory efficacy of IVIG has been attrib-
uted to both F(ab’)2- and Fc-dependent mechanisms [52].
Fc fragments appear to be required for IVIG-mediated
protection in several antibody-mediated autoimmune dis-
ease models such as the K/BxN serum transfer arthritis
model and the antiplatelet monoclonal antibody 6A6-
mediated model for immune thrombocytopenia [15, 18,
53, 54]. In contrast to EAE, the aforementioned auto-
immune disease models are largely mediated by IgG-
dependent activation of innate immune effector cells via
crosslinking of cellular FcγRs [17, 55–68]. Antibodies
raised by the immunization with MOG peptide during
EAE induction do not facilitate disease susceptibility, as
mice lacking B cells develop severe EAE [69–71]. Mice
deficient in the FcR-associated signaling unit, the common
γ-chain, are EAE resistant; however, the protective effect
of FcγR deficiency was shown to be dependent on comple-
ment activation but independent of antibodies and im-
mune complexes binding to FcγR expressing cells [72, 73].
The finding that treatment with F(ab’)2 fragments strongly
reduced effector T cell numbers and pro-inflammatory
cytokine production and fully phenocopied the protection
achieved with equimolar amounts of IVIG indicates that
F(ab’)2 fragments are the key in mediating the clinical
efficacy of IVIG in EAE.
A prime example of an F(ab’)2-dependent mechanism
is toxic epidermal necrolysis (Lyell syndrome), in which
the Fas–FasL (also called CD95–CD95L) receptor–lig-
and pathway is a crucial mediator for the skin blistering
associated with this condition. By blocking this inter-
action, CD95-specific antibodies in IVIG preparations
can interfere with this autoimmune pathology [74]. The
human immune repertoire recognizes a broad range of
antigens which is reflected by the finding that IVIG
preparations contain antibodies with specificity not only
for foreign, microbial antigens but also for host factors
such as attachment sites for viral and bacterial patho-
gens [38]. For example, IVIG binds to glycans important
for host-pathogen interactions [38] and is reported to
contain antibodies binding to pertussis toxin [75, 76],
which is used along with CFA to facilitate active EAE
induction.
Our study shows that antibodies binding to mycobacter-
ial antigens are present in IVIG preparations, inhibit the
immunogenicity of CFA necessary for EAE induction, and
ameliorate disease development. These findings might
partly explain the discrepancy between the clinical efficacy
of IVIG in the EAE model which requires active
immunization with microbial adjuvant [2–8] and MS pa-
tients where IVIG has limited efficacy in reducing relapse
rate and disease progression.
Conclusions
IVIG proved to be an efficient anti-inflammatory treat-
ment for a growing number of neuroinflammatory dis-
eases and protects against the development of actively
induced EAE. Although EAE is a widely used animal
model for MS, there is an apparent discrepancy in the
clinical efficacy of IVIG in MS and EAE. Using one IVIG
preparation (Privigen), we found that the protective ef-
fect of polyclonal IgG is lost in the adoptive transfer
model of EAE and requires prophylactic administration
during disease induction. IVIG-derived Fc fragments are
not required for protection against EAE, since adminis-
tration of F(ab’)2 fragments fully recapitulate the clinical
efficacy of IVIG. F(ab’)2-mediated protection of actively
induced EAE is associated with decreased innate im-
mune cell activation and effector T cell responses upon
vaccination. As a potential mechanism, we demonstrate
that IVIG binds to mycobacterial antigens in Freund’s
complete adjuvant which is required to facilitate active
EAE induction. These findings might partly explain the
discrepancy of IVIG efficacy in MS and the EAE model
which requires active immunization with microbial
adjuvant.
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